ILSI-Biomed Israel

Six trends that will change the fundamentals of pharmaceutical distribution

The latest report in the Pharma 2020 series from PwC US outlines six trends that will fundamentally change the way pharmaceutical companies make and distribute products. “The current pharmaceutical supply chain worked well when the ‘blockbuster’ paradigm prevailed, but pharma’s focus in a post-health reform world is shifting from products to patients, and their supply chain processes need to adopt the speed and agility of other, more consumer-oriented industries such as consumer electroni...

Quality Assurance Manager needed

Quality Assurance Manager Position Specifications 1. Knowledge/Educational Requirements • Extensive knowledge of quality principles and requirements • Good understanding of Medical Device Regulatory requirements • Good understanding of general management techniques. • Degree level with scientific and company management background. • 3-5 years successfull experience in Medical Device companies 2. Skills and Abilities • Able to think clearly in order to create systems. • Able...

Meet the speakers: STEPHEN N. OESTERLE, M.D.

STEPHEN N. OESTERLE, M.D. Senior Vice President for Medicine and Technology Stephen N. Oesterle, M.D., joined the company in 2002 as Senior Vice President for Medicine and Technology. In this role, Steve provides executive leadership for Medtronic scientific research, formation of technological strategies and continued development of strong cooperative relationships with the world's medical communities, technical universities, financial institutions and emerging medical device companies...

JSBarkats Sponsors 2011 US/Israel Venture Summit in New York

NEW YORK, March 22, 2011 (GLOBE NEWSWIRE) -- JSBarkats PLLC ("JSBarkats") announced today that it will be sponsoring the 2011 US/Israel Venture Summit in New York, March 29th -- 30th, 2011. The US/Israel Venture Summit, presented by youngStartup Ventures, is the premier gathering where cutting-edge Israeli startups meet top venture capitalists, angel investors, Corporate VCs and investment bankers from throughout North America. See http://www.youngstartup.com/usisrael2011/overview.php. ...

BrainStorm Raises $3.6 M To Launch Phase I/II Trial for ALS.

The recent appointment of Adrian Harel as the CEO of BrainStorm Cell Therapeutics (OTCBB: BCLI) signals the beginning of a new era both for the company and for its new top exec. BrainStorm, after several hurdle-crossing years of pre-clinical testing and validation of its autologous stem cell therapy, is about to become the first Israeli company to reach the clinical trial stage with a differentiated stem cell-based therapy. The company`s Phase I/II trial, expected to begin in the spring,...

Robots back breakthrough surgery.

SpineAssist – an Israeli invention – is revolutionizing delicate spinal surgery. Judy Siegel-Itzkovich spoke to the innovative company’s CEO. Many patients scheduled for a major spinal operation naturally worry that they might find themselves in a wheelchair due to a surgical error, or simple bad luck. While this happens only rarely, it is a possibility. The results of orthopedic surgery are as good as the specialist who performs it – but today, the risk is much reduced. Not only is there...

Prof. Michael Karin and Prof. Alexander Polyakov – Winners of 2010 Harvey Prize

Prof. Michael Karin and Prof. Alexander Polyakov are the winners of the Technion’s 2010 Harvey Prize. Prof. Karin, from the University of California, San Diego, will receive the prize in the field of human health. He discovered the strong link between obesity, inflammation and cancer. The judges decided to award the prize to Prof. Karin for “his pioneering contribution that led to deciphering the molecular mechanism through which mammalian cells react to cytokines which cause inflammation...

Meet the speakers: Francois Maisonrouge, Senior Managing Director, Evercore Partners.

Francois Maisonrouge is a Senior Managing Director in advisory business with 25 years of relevant experience. At Evercore, Mr. Maisonrouge was involved in advising Wyeth on its sale to Pfizer, Sanofiaventis on its purchase of Merck's 50% stake in Merial including an option to potentially merge Merial with Intervet / Schering-Plough Animal Health in the future, TPG on its acquisition of IMS Health, De Ruiter on its sale to Monsanto, Bracco on its acquisition of E-Z-Em, and the sale of Op...

Job Offers in Israel

Pre Clinical Manager Niti Surgical is looking for a Pre-Clinical Manager who will be planning & conducting the company preclinical investigations during the development stages of its future products The candidate will have to evaluate the Biological activity of the company’s devices, both in terms of safety & efficacy. Responsibilities begin with establishing of the study protocol, continue with the submission of preclinical trials applications, through monitoring of the study c...

Vaxil’s TB vaccine successfully passes first stage in animal studies

Nes-Ziona, 8th March, 2011. Vaxil Biotherapeutics Ltd., a clinical stage developer of innovative therapeutic vaccines announced today that MTbuVax, its vaccine against the lethal bacteria Mycobacterium Tuberculosis (MTb) has proven to manifest effective induction of immune response in mice. The studies demonstrated that mice vaccinated with MTbuVax produced potent CD4+ and CD8+ T-cell immunity that specifically proliferated in response to the MTbuVax vaccine. In addition, T-cells from vac...